English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Indium- 111  ( 111 In) has an appropriate half-life ( T  1/2  = 67 h) and energy characteristics for cancer diagnosis via  γ -ray imaging and cancer therapy with Auger electrons. The aim of our study is to evaluate the potential of [ 111 In]In-DO3A-NHS-nimotuzumab as a theranostic agent for radioimmunoimaging (RII) and radioimmunotherapy (RIT) against human glioma xenografts in mice. We explored the chelators DO3A-NHS and DOTA-p-SCN-Bz to optimize  111 In radiolabeling efficiency of nimotuzumab. The radiopharmaceuticals were purified by PD-10 mini-column and their  in vitro  stabilities were assessed. We investigated the biodistribution of [ 111 In]In-DO3A-NHS-nimotuzumab as it had relatively superior labeling efficiency and stability  in vitro . We conducted SPECT imaging on mice bearing glioma (U87MG) xenografts, which were injected with ∼3.7 MBq of [ 111 In]In-DO3A-NHS-nimotuzumab. The  in vivo  radiotherapeutic effects of [ 111 In]In-DO3A-NHS-nimotuzumab was analyzed via injecting a single 37 MBq dose, 2 × 18 MBq doses, or 2 × 37 MBq doses into mice bearing U87MG xenografts. The control groups were administered either 30 μg nimotuzumab or saline. The radiochemical yields of [ 111 In]In-DO3A-NHS-nimotuzumab and [ 111 In]In-DOTA-p-SCN-Bz-nimotuzumab were &gt; 85% and &gt; 75%, respectively. [ 111 In]In-DO3A-NHS-nimotuzumab had &gt; 95% radiochemical purity and was more stable  in vitro  than [ 111 In]In-DOTA-p-SCN-Bz-nimotuzumab. Biodistribution study demonstrated that [ 111 In]In-DO3A-NHS-nimotuzumab was highly stable  in vivo . SPECT imaging disclosed that [ 111 In]In-DO3A-NHS-nimotuzumab had excellent targeted tumor uptake and retained in tumors for 24 and 72 h. All [ 111 In]In-DO3A-NHS-nimotuzumab treatments substantially inhibited tumor growth over the controls. The 2 × 37 MBq treatment was particularly efficacious, and presented with survival time prolonged by ≤66 days. In contrast, the survival time of the control group was only 30 days. In our study, we developed an optimized synthesis protocol for radiopharmaceutical  111 In-DO3A-NHS-nimotuzumab and demonstrated that it is a promising theranostic agent. It could be highly efficacious in RII and RIT against EGFR-expressing glioma.

A novel theranostic probe [ 111 In]In-DO3A-NHS-nimotuzumab in glioma xenograft